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Abstract
 Introduction—Recurrent joint hemarthroses due to hemophilia (Factor VIII and Factor IX 
deficiency) often lead to invasive orthopedic interventions to decrease frequency of bleeding 
and/or to alleviate pain associated with end-stage hemophilic arthropathy.
 Aim—Identify trends in invasive orthopedic interventions among people with hemophilia who 
were enrolled in the Universal Data Collection (UDC) program during the period 2000–2010.
 Methods—Data were collected from 130 hemophilia treatment centers in the United States 
annually during the period 2000–2010, in collaboration with the Centers for Disease Control and 
Prevention (CDC). The number of visits in which an invasive orthopedic intervention was reported 
was expressed as a proportion of the total visits in each year of the program. Invasive orthopedic 
interventions consisted of arthroplasty, arthrodesis, and synovectomy. Joints included in this study 
were the shoulder, elbow, hip, knee, and ankle.
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 Results—A 5.6% decrease in all invasive orthopedic interventions in all joints of people with 
hemophilia enrolled in the UDC program over the 11-year study period was observed.
 Conclusions—These data reflect a declining trend in invasive orthopedic interventions in 
people with hemophilia. Further research is needed to understand the characteristics that may 
influence invasive orthopedic interventions.
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 Introduction
Hemarthrosis is a common clinical manifestation of hemophilia (Factor VIII or FIX 
deficiency). Recurrent hemarthrosis can cause chronic joint disease resulting in pain, 
decreased range of motion, and decreased ability to participate in activities, all of which 
affect quality of life [1,2]. Orthopedic interventions often are used to decrease pain, decrease 
bleeding episodes, and maintain or improve quality of life for individuals with severe 
hemophilic joint disease [3].
The Universal Data Collection (UDC) program [2], in collaboration with federally supported 
hemophilia treatment centers (HTCs) across the United States, included data from people 
with bleeding disorders who have undergone an invasive orthopedic intervention. End-stage 
invasive orthopedic interventions such as arthroplasty and arthrodesis are performed 
primarily to alleviate pain [4,5]. Non-end-stage invasive orthopedic interventions in 
hemophilia are performed to disrupt the cycle of recurrent hemarthroses, delay end-stage 
arthropathy, relieve pain and preserve joint structure [6–8]. Non end-stage invasive 
interventions may include but are not limited to synovectomy, labral repairs, meniscal 
repairs and allografts.
The purpose of this study is to report trends in the occurrence of invasive orthopedic 
interventions, such as arthrodesis, arthroplasty, and synovectomy, among the population with 
hemophilia A or B, who were enrolled in the UDC program from 2000 to 2010. We 
hypothesized that there would be a decreasing trend in orthopedic interventions for end-
stage arthropathy and an increase in non-end stage arthropathy procedures.
 Methods
Data were collected from patients at approximately 130 U.S. HTCs annually during the 
period 1998–2011 under the UDC program, in collaboration with the Centers for Disease 
Control and Prevention (CDC). Approximately 24,000 or 80% of individuals with a bleeding 
disorder seen at an HTC have enrolled in the UDC program from 1998 until September 2011 
[2,9]. With input and assistance from hematologists, physical therapists, nurses, other 
providers of hemophilia care and people with bleeding disorders, the UDC program was 
developed as a standardized data collection tool for the surveillance of people with bleeding 
disorders. Participation was voluntary and required informed consent from participants (or 
parents of minors). Each participating HTC and the CDC provided institutional review board 
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approval. HTC medical providers collected data on demographic characteristics and clinical 
characteristics on an annual basis. Historic information was collected on an initial 
registration form for each participant. Data collected represented a mix of self-reports and 
medical chart abstraction.
 Study population
 Inclusion and exclusion—Universal Data Collection program participants with a 
diagnosis of hemophilia A or B, over the age of 2 years who completed at least one UDC 
visit during the years 2000–2010 were eligible for inclusion in this study. Eligible UDC 
program participants with incomplete or missing information on variables of interest were 
excluded from the analysis. Variables of interest were type of invasive orthopedic 
intervention (arthroplasty, arthrodesis, synovectomy and ‘other’), presence of inhibitor, type 
of factor replacement, diagnosis, and age. Severity of hemophilia classification is based on 
plasma levels of Factor VIII or IX activity. Factor levels < 1% are classified as severe, 
between 1% and 5% is moderate and >5% and <40% of normal is mild [10].
 Outcome measures
The outcomes of interest for our study were the proportions of individuals with hemophilia 
who reported invasive orthopedic interventions for each year of the study. To maintain 
consistency, proportions were reported for sub-groups as well. However, in a few instances 
where very small proportions were encountered, they were expressed as a percent. The UDC 
program data consists of invasive orthopedic interventions on 10 joints: bilateral shoulders, 
elbows, hips, knees, and ankles. In the UDC program all orthopedic interventions were 
recorded in one of the following categories: arthrodesis, arthroplasty, synovectomy, and 
‘other’. The ‘other’ category represented a nonspecific group of orthopedic interventions 
that could not be categorized under one of the first three categories. Arthrodesis and 
arthroplasty procedures were counted once per joint, per side, per subject while 
synovectomies and ‘other’ procedures were not limited in number per side or per joint. In 
the hemophilia population, synovectomies are typically performed to decrease pain and 
recurrence of bleeding; therefore multiple procedures of this type could have been 
performed in a year. The non-specific ‘other’ procedures may also be recorded multiple 
times within a year in the same joint due to trauma or revision/complication of an orthopedic 
procedure.
For a few participants who reported arthrodesis and arthroplasty procedures more than once 
per joint per side, only the first report of their orthopedic intervention was counted. Since 
both arthrodesis and arthroplasty procedures are interventions for end-stage joint disease and 
typically do not occur repeatedly in the same joint, unless there are significant 
complications, we discounted the repeat reports of either procedure on the same side of the 
same joint. Therefore, this analysis does not include any repeated procedures that are 
indicative of complications. Synovectomy in the UDC program was differentiated into 
groupings of arthroscopic, open, or radioisotopic.
The calculated proportions were plotted as line graphs to show any trends over the 11-year 
period. Overall proportions, as well as stratifications by various characteristics of interest 
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such as diagnosis (hemophilia A or B), severity, age, factor replacement method, and 
inhibitor presence, were calculated and plotted. Proportions for each year was determined by 
counting all participants who reported an invasive orthopedic intervention during a UDC 
visit divided by the total number of eligible participants with a UDC program visit on record 
for that year.
For analysis and plotting purposes in this study, age was categorized into four groups: 2–20 
years of age, 20–39 years of age, 40–59 years of age, and 60 years of age or older. Age 
groups were chosen in 20-year intervals for people up to 59 years of age. All participants 60 
years of age or older were grouped together, as there were relatively few people in this oldest 
age group.
Approximately 15–30% of patients with FVIII deficiency and 2–5% of patients with FIX 
deficiency develop an inhibitor, an alloimmune neutralizing antibody [11]. Inhibitor status or 
presence for each study year was defined as positive if the recorded inhibitor titer in that 
year was >1 Bethesda unit or if the person was receiving immune tolerance therapy. Because 
inhibitor titer can change from one year to another [12], and taking a conservative approach, 
for this study’s purposes, a person was categorized as inhibitor positive if she or he was 
positive for the presence of an inhibitor in the year prior to and the year of an invasive 
orthopedic intervention. Negative inhibitor status was defined as not having a recorded 
inhibitor in the year prior to and the year of an orthopedic intervention.
The UDC program defines continuous prophylaxis therapy as a person receiving treatment 
product on a regular schedule to prevent any and all bleeding with the expectation to 
continue indefinitely. Continuous prophylaxis status for this study was defined as positive 
when an individual was recorded in the UDC program as being on continuous prophylaxis 
for both the year prior to and the year of the orthopedic intervention. On demand or 
intermittent prophylaxis were coded as negative for prophylaxis in our study.
 Statistical analysis
The proportion of individuals with hemophilia reporting an invasive orthopedic intervention 
in a given year was calculated by dividing total number of participants with hemophilia who 
reported an invasive orthopedic intervention by the total number of individuals with 
hemophilia who had a UDC visit that year. The calculated proportions were plotted and 
significant trends (P < 0.05) were identified using Cochran–Armitage trend test. The output 
for this paper was generated using SAS software (SAS Institute Inc., Cary, NC, USA) [13].
 Results
A total of 66,284 annual study visits of individuals with hemophilia participated in the UDC 
program from 2000 to 2010. Of these individuals 78.9% were diagnosed with hemophilia A 
and 21.1% with hemophilia B. Close to half (49.6%) of participants had severe hemophilia, 
31.5% had moderate hemophilia, 18.8% had mild hemophilia and 0.1% had an unknown 
severity level of hemophilia during the study. Table 1 includes select demographic and 
clinical characteristics of the UDC participants who completed an annual UDC visit by year 
of the visit.
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Enrollees reported a total of 2582 invasive orthopedic interventions over the entire study 
period. Table 2 represents the distribution of invasive orthopedic interventions reported over 
the study period. We found the knee joint had the largest proportion of invasive orthopedic 
interventions with 1172 (45.4%) of all orthopedic interventions, followed by the ankle (658, 
25.5%), elbow (497, 19.2%), hip (169, 6.5%), and shoulder (86, 3.3%). Overall the most 
commonly reported invasive orthopedic interventions were synovectomies (1180, 45.7%), 
followed by arthroplasties (669, 25.9%), ‘other’ invasive orthopedic interventions (556, 
23.5%), and arthrodesis (177, 6.9%).
We found arthroplasty was the most frequent invasive orthopedic intervention reported on 
the hip (124, 73.4%) and knee joint (473, 40.4%), accounting for about three-quarters of all 
orthopedic interventions reported. Synovectomy (all three types combined) was the most 
frequently reported invasive orthopedic intervention on the ankle joint (355, 54.0%). In the 
upper extremity, synovectomy was the most frequently reported invasive orthopedic 
intervention on the elbow joint (343, 69.0%), whereas procedures categorized as ‘other’ 
were the most commonly reported orthopedic interventions on the shoulder joint (Table 2).
 Invasive orthopedic interventions trends 2000–2010
The UDC program data reflects a 5.6% declining trend in all invasive orthopedic 
interventions for all joints during 2000–2010 (Fig. 1). In the year 2000, 7.2% of the 
enrollees reported undergoing an orthopedic intervention during the year prior to 2000; 
whereas in the last year of the study (2010), only 1.7% reported undergoing an invasive 
orthopedic intervention during the previous year. This trend is statistically significant (P < 
0.01).
To explore whether or not the observed overall declining trend in the use of invasive 
orthopedic interventions was consistent across strata of characteristics that could influence 
use of orthopedic interventions, separate graphs that displayed trends by various variables of 
interest (diagnosis, age, inhibitor status, prophylaxis status) were produced. The proportions 
of orthopedic interventions at the start of the study (2000) and at the end (2010), along with 
the statistical significance (P-value) of the Cochran–Armitage, trend test, for various 
characteristics of interest (type of orthopedic intervention, joint diagnosis, age, inhibitor 
status and prophylaxis status), are summarized in Table 3. All trend tests revealed a 
statistically significant decline over the decade. All strata showed strong significance with 
all P-values <0.01.
 Invasive orthopedic interventions by diagnosis
The data show an overall decreasing trend in the reported number of invasive orthopedic 
interventions for participants regardless of the type or severity of hemophilia. Throughout 
the 11-year study period the proportion of enrollees with hemophilia A was approximately 
80% and hemophilia B was 20%. During the study period, both groups of people with 
hemophilia A or B showed a decrease in invasive orthopedic interventions by 5.8% and 
4.6% respectively (Fig. 2). With the exception of 2003, people with mild hemophilia 
consistently reported fewer orthopedic interventions than people with moderate hemophilia 
who in turn showed consistently fewer orthopedic interventions than people with a severe 
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form of the disorder (Fig. 3). The percentages reported in the year 2000 and in the year 2010 
represent a 2.4%, 3.9% and 7.2% reduction of invasive orthopedic interventions for people 
with mild, moderate and severe hemophilia respectively. These trends are statistically 
significant (P < 0.01).
 Invasive orthopedic interventions by age group
A decreasing trend in all invasive orthopedic interventions was observed among all age 
groups (Fig. 4). As expected, considerable variation was seen in reported proportions of 
orthopedic interventions across all age groups. Larger differences in reported proportions of 
orthopedic interventions were observed between people in different age groups in 2000 than 
at the end of the study period in 2010. The greatest change (8.7%) was observed among the 
20–39 years-of-age group, in which the proportion of invasive orthopedic interventions 
dropped from 11.2% in 2000 to 2.6% in 2010. A significant change (P < 0.01) was observed 
among all age strata.
 Invasive orthopedic interventions by inhibitor status
We observed a reduction of 7.0% from 2000 to 2010 in invasive orthopedic interventions in 
people with hemophilia who had a positive inhibitor status and a 5.5% reduction was 
observed in individuals with a negative inhibitor status (Fig. 5). Much larger year-to-year 
variations were observed among people positive for inhibitors than among those negative for 
inhibitors. Excluding the first few years of the study period, a larger proportion of people 
with inhibitors reported undergoing an orthopedic intervention than people without inhibitor.
 Invasive orthopedic interventions by prophylaxis status
Among all participants, regardless of their prophylaxis status, a declining trend was 
identified for all invasive orthopedic interventions (Fig. 6). Throughout the study, a higher 
proportion of people on intermittent prophylaxis or on demand therapy reported undergoing 
an orthopedic intervention than did those utilizing continuous prophylaxis. At the start of the 
study, almost three times as many orthopedic interventions were reported among people on 
intermittent prophylaxis or on demand therapy (12.06) compared to those who were utilizing 
continuous prophylaxis (4.61). By the final years of the study, this proportion had decreased 
to comparable levels in both groups (2.29, 1.57). A reduction of 9.8% in intermittent or on 
demand group and 3.0% in the continuous prophylaxis group was observed for orthopedic 
interventions by the year 2010; the trend test was significant for both groups.
 Discussion
In our study of a large cohort of people with hemophilia enrolled in the UDC in the United 
States, who had invasive orthopedic interventions, the descriptive trends show a declining 
number of reported orthopedic interventions for all joints, types and severity of hemophilia, 
age groups, and groups categorized by inhibitor status and prophylaxis status. Specifically, 
people with hemophilia enrolled in the UDC program had an average of 5.6% fewer invasive 
orthopedic interventions by the end of the 11-year study period. Our data show a decreasing 
trend in both end-stage arthropathy procedures (arthrodesis and arthroplasty) and non-end 
stage arthropathy procedures (synovectomy and all other invasive interventions). This 
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information confirms what many hemophilia providers have observed over the years of less 
joint morbidity leading to less invasive orthopedic procedures in the hemophilia population. 
Understanding the magnitude and trend of invasive orthopedic interventions performed 
provides a foundation for identifying characteristics associated with orthopedic interventions 
in people with hemophilia.
The effects of early onset continuous prophylaxis are well documented [14–16]; therefore, 
the role of prophylaxis in the overall decrease in the number of invasive orthopedic 
interventions cannot be ruled out. Advances such as the availability of high-quality factor 
concentrates and recombinant factor concentrates, and the adoption of primary prophylaxis 
for individuals with severe hemophilia as the standard of care adopted by developed 
countries [15,16], might decrease the need for orthopedic interventions over time for 
individuals with hemophilia due to general improvement in joint health and management of 
joint disease. Our data show that over the study period, the number of UDC enrollees on 
continuous prophylaxis therapy and on demand therapy reporting invasive orthopedic 
decreased. The on demand therapy group had a 9.8% decrease in invasive orthopedic 
interventions compared to the 3% change in the continuous prophylaxis therapy group. The 
authors hypothesize that over the study period, since approximately over 50% of the people 
with hemophilia who had undergone invasive orthopedic interventions had severe disease, 
may have changed their factor replacement practice from on demand therapy to continuous 
prophylaxis. Our study did not examine this specifically.
An inhibitor creates challenges in obtaining proper factor replacement levels to control 
bleeding which leads to severe arthropathy and increased risk of bleeding during invasive 
procedures [17–20]. Despite the increased accessibility to factor replacement and 
advancements in factor replacement products, an increase in the number of inhibitor patients 
having orthopedic interventions has been hypothesized by the authors but not observed in 
our study.
The advancement of minimal invasive synovectomies either by arthroscopy or radioisotope 
has increased over the years, resulting in a reduction of a more invasive procedure, such as 
an open synovectomy [21,22]. We anticipated the number of non-end stage procedures such 
as synovectomy would increase overall; however, our study shows an overall decrease in all 
three types of synovectomies (1.4% arthroscopic, 0.95% open and 0.83% radioisotopic). We 
hypothesize the decrease in synovectomies may be related to an increase use of continuous 
prophylaxis in our study population resulting in overall decrease hemarthrosis.
The category of ‘other’, a group of non-specific orthopedic invasive interventions, shows a 
slow increase over the study period. The authors hypothesize that because the data for 
‘other’ invasive orthopedic interventions refer to a non-specific intervention, many non end-
stage interventions such as joint injections and unrelated bleeding disorders complications 
interventions such as ligamentous repairs are categorized here.
The demographic and clinical characteristics of our study population reflect what previously 
has been reported in the literature on the occurrence of hemophilia in the United States 
population [23]. There are limitations to this study to consider. Data were collected from 
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individuals who were enrolled in the UDC program and, therefore, did not represent all 
individuals with hemophilia in the United States. Additionally, our study consisted of 
retrospective reporting, which has inherent limitations of underreporting of orthopedic 
interventions as well as inaccurate reporting (e.g. joint fusion might be recorded under the 
‘other’ category vs. being included in the ‘arthrodesis’ category).
 Conclusions
Upon examination of proportions of invasive orthopedic interventions in people with 
hemophilia enrolled in the UDC program during the period 2000–2010, results reveal a 
decreasing trend in invasive orthopedic interventions across all joints, diagnoses, and age 
groups regardless of their inhibitor or prophylaxis status. Changes in the standard of care for 
people with hemophilia, to an early and aggressive factor replacement protocol, as well as 
availability of high quality factor products are possible reasons for the declining trend in 
orthopedic interventions in people with hemophilia. Further prospective studies with detailed 
analysis of characteristics that may influence rates of invasive orthopedic interventions, 
including factor replacement protocols are recommended.
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All invasive orthopedic interventions (arthrodesis, arthroplasty, synovectomy, and other) 
summed over all joints. Other, represents a non-specific group of invasive orthopedic 
interventions not categorized as arthrodesis, arthroplasty or synovectomy.
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All invasive orthopedic interventions (arthrodesis, arthroplasty, synovectomy, and other) by 
diagnosis. Other, represents a non-specific group of invasive orthopedic interventions not 
categorized as arthrodesis, arthroplasty or synovectomy.
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All invasive orthopedic interventions (arthrodesis, arthroplasty, synovectomy, and other) by 
hemophilia severity. Figure excludes 75 individuals whose severity was unknown. Other, 
represents a non-specific group of invasive orthopedic interventions not categorized as 
arthrodesis, arthroplasty or synovectomy.
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All invasive orthopedic interventions (arthrodesis, arthroplasty, synovectomy, and other) by 
age groups (in years). Other, represents a non-specific group of invasive orthopedic 
interventions not categorized as arthrodesis, arthroplasty or synovectomy.
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All invasive orthopedic interventions (arthrodesis, arthroplasty, synovectomy, and other) by 
inhibitor status. Inhibitor negative is no reported inhibitor presence in the year prior to and 
year of an orthopedic intervention. Inhibitor positive is presence of inhibitor the year prior to 
and year of an orthopedic intervention. Other, represents a non-specific group of invasive 
orthopedic interventions not categorized as arthrodesis, arthroplasty or synovectomy.
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All invasive orthopedic interventions (arthrodesis, arthroplasty, synovectomy, and other) by 
factor use. ‘On demand’ is defined as intermittent use of factor replacement as recorded by 
the Universal Data Collection (UDC) program in the year prior to and year of an invasive 
orthopedic intervention. Continuous prophylaxis is defined recorded continuous prophylaxis 
by the UDC program in the year prior to and year of an invasive orthopedic intervention. 
Other, represents a non-specific group of invasive orthopedic interventions not categorized 
as arthrodesis, arthroplasty or synovectomy.
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Table 3
Proportion of Universal Data Collection program enrollees reporting an invasive orthopedic intervention (IOI) 
in the starting and ending years of the study, along with the statistical significance of the trend test.
Percentage of IOI in 2000 Percentage of IOI in 2010 Minimum percentage value (Year) P-value*
All IOIs combined, all joints   7.21 1.65 1.62 (2007) <0.01
Individual IOIs, all joints
 Arthrodesis   0.71 0.15 0.06 (2008) <0.01
 Arthroplasty   1.96 0.55 0.52 (2007) <0.01
 Synovectomy
  Arthroscopic   1.79 0.44 0.38 (2006) <0.01
  Open   1.10 0.15 0.13 (2007) <0.01
  Radioscopic   1.01 0.18 0.15 (2006) <0.01
 Other IOIs   1.86 0.29 0.29 (2010) <0.01
Individual joints, all IOIs
 Hip   0.50 0.14 0.07 (2009) <0.01
 Knee   4.53 0.76 0.76 (2010) <0.01
 Ankle   2.24 0.52 0.38 (2009) <0.01
 Shoulder   0.17 0.06 0.03 (2007) <0.01
 Elbow   1.36 0.38 0.35 (2009) <0.01
Diagnosis
 Hemophilia A   7.57 1.75 1.65 (2007) <0.01
 Hemophilia B   5.81 1.25 1.25 (2010) <0.01
Hemophilia severity
 Mild   3.19 0.76 0.54 (2009) <0.01
 Moderate   5.34 1.41 1.36 (2009) <0.01
 Severe   9.27 2.10 2.03 (2007) <0.01
Age in years
 <20   3.86 0.71 0.56 (2009) <0.01
 20–39 11.23 2.56 2.32 (2008) <0.01
 40–59 14.04 3.06 2.81 (2007) <0.01
 ≥60   8.51 2.48 1.63 (2009) <0.01
Inhibitor status
 Positive   8.06 1.00 1.00 (2010) <0.01
 Negative   7.16 1.68 1.64 (2007) <0.01
Prophylaxis status
 Continuous prophylaxis   4.61 1.57 0.12 (2007) <0.01
 Intermittent or on demand 12.06 2.29 2.24 (2008) <0.01
*
Cochran–Armitage Trend Test.
IOI, invasive orthopedic intervention, represents a non-specific group of invasive orthopedic interventions not categorized as arthrodesis, 
arthroplasty or synovectomy.
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